Nektar Therapeutics: financial statements

NKTRNASDAQHealthcare · Pharmaceutical Preparations

Price

$33.99

November 19, 2026Market cap $1.2B

What Ploutos Investor adds for Nektar Therapeutics

Part of Ploutos Investor, €9.99 a month

See the plans
  • The full history: 17 fiscal years, from 2009
  • The estimated fair value, with its range and its certainty
  • The full analysis, 18 a month
  • More questions to the chat on its filings
  • Excel with every year
  • An email when it reports, changes its dividend or an officer buys

Sign in with a free account to see the last 5 fiscal years.

Financial statements

Each fiscal year's income statement, balance sheet and cash flow as the company filed them, and the latest quarters.

2023–2025 fiscal years

Click a line to see it on the chart.

Revenue

-21.7% a year over 2 years

Line202320242025Average a year
Revenue $90M$98M$55M-21.7%
Cost of revenue $34M$31M$0
Gross profit $56M$68M$55M-1.0%
Operating income -$264M-$105M-$140M
Net income -$276M-$119M-$164M
Earnings per share -$21.75-$8.68-$9.73
Earnings per share, basic -$21.75-$8.68-$9.73
Margins
Gross margin 62.5%68.8%100.0%
Operating margin -292.6%-106.9%-253.7%
Net margin -306.3%-120.9%-297.1%

Financial statements

NKTR's revenue, profits and cash flows from 2009 to 2022, 14 more fiscal years

Part of Ploutos Investor, €9.99 a month

See the plans

Sign in with a free account to see the last 5 fiscal years.

By segment

Revenue and operating income by business segment or by product, as the company itself reports them in each year's 10-K. Each year from the latest filing that carries it, so a segment renamed or re-cut shows in its current form.

  • 2023: Non Cash Royalties $69M, License Collaboration And Other Revenue $520.0K, Product $21M
  • 2024: Non Cash Royalties $64M, License Collaboration And Other Revenue $597.0K, Product $34M
  • 2025: Non Cash Royalties $55M, License Collaboration And Other Revenue $300.0K, Product –
Product202320242025Share 2025
Non Cash Royalties$69M$64M$55M99%
License Collaboration And Other Revenue$520.0K$597.0K$300.0K0.5%

By segment

NKTR's revenue by product line from 2016 to 2022, 7 more fiscal years

Part of Ploutos Investor, €9.99 a month

See the plans

Sign in with a free account to see the last 5 fiscal years.

From the XBRL of 11 of the company's annual reports to the SEC (ASC 280). Amounts in dollars.

Amounts are in dollars as the company filed them in its annual reports (10-K or 20-F). Those reporting in another currency are converted at each fiscal year-end rate. Shares and earnings per share are adjusted for splits.

Debt and obligations

What the company owes beyond the loans on its balance sheet, and when it pays, from the notes to its annual report: debt maturities, leases, pension plans, goodwill by segment, and how it gets to the tax it pays.

$86M Leases0.1% Effective tax rate

Leases

Dec 31, 2025

Operating leases

$86M

Finance leases

–

The liability is the present value of the rent still to pay, at December 31, 2025. It is not counted in the ladder's debt. The filing

From the statutory to the effective tax rate, 2025

Dec 31, 2025

Statutory rate

21.0%

Effective rate

0.1%

-20.9 pts

The company paid 0.1% in tax on its profit, 20.9 points below the US federal rate (21.0%). Below, the reasons it gives.

The lines the company states do not reach its effective rate, so we do not show them. Both rates are the filing's. The filing

Claims ahead of shareholders

What stands between the business and its shareholders besides the debt, and the financial assets on the other side, from the latest balance sheet.

$339M securities and stakes

Besides its debt, no other claim large enough to list ranks ahead of the shares.

On the other side, it holds $339M of long-term securities and stakes in other companies, at the value in its accounts, about 29% of the market value.

On the other side

at Sep 30, 2026
$339M

From the balance sheet of September 30, 2026. The retirement and environmental lines and the pension deficit come from the latest annual report when the quarter's filing does not state them, each with its own date. Market value at the price of November 19, 2026. A line is listed when it is at least 0.5% of the market value. A description of the balance sheet, not a valuation.

The full analysis

What do Nektar Therapeutics's filings show?

These are Nektar Therapeutics's figures from its filings. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.

  • A fair value range built from the filings
  • Earnings quality, debt and red flags
  • Insider and institutional moves
  • The case for and the case against

Questions about NKTR's financials

Didn't find what you were looking for?

Ask us
How much revenue did NKTR have in 2025?

Nektar Therapeutics had revenue of $55M and net income of -$164M in fiscal 2025, a net margin of -297.1%.

How much debt does NKTR have?

On December 31, 2025 Nektar Therapeutics had total assets of $280M, debt of – and shareholders' equity of $90M.

How much free cash flow does NKTR have?

In fiscal 2025 Nektar Therapeutics had cash from operations of -$209M and spent $171.0K on capital expenditure, leaving -$209M of free cash flow.

Where are the figures from?

From Nektar Therapeutics's annual and quarterly reports to the SEC, read from the structured data (XBRL) it files itself.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.